ICG-001

ICG-001拮抗Wnt/β-catenin/TCF介导的转录,并特异性结合到启动子结合蛋白(CBP),IC50为3 μM,但不能结合到相关的转录共激活因子p300上。ICG-001 可诱导凋亡。

ICG-001 Chemical Structure

ICG-001 Chemical Structure

CAS: 780757-88-2 (relative stereochemistry); 847591-62-2 (absolute stereochemistry)

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1377.83 现货
5mg RMB 976.49 现货
25mg RMB 3835.04 现货
100mg RMB 10401.3 现货
1g RMB 13677.3 现货
更大包装 有超大折扣

400-668-6834

info@selleck.cn

免费分装
免费预溶

客户使用Selleck的ICG-001发表文献182

产品质控

批次: 纯度: 99.75%
99.34

常与ICG-001一起在实验中被使用的化合物

Auranofin


Foscenvivint和Auranofin协同抑制皮下异种移植小鼠模型中结肠癌的生长,并抑制肺转移小鼠模型中的转移。

Lin Z, et al. Front Oncol. 2021; 11: 738085.

Paclitaxel


Foscenvivint可改善Paclitaxel诱导的FOXM1表达和癌症干细胞(CSC)表型以及体外肿瘤启动能力的增加。

Ring A, et al. Cancers (Basel). 2018 Dec 19;10(12):525.

(+)-JQ1


Foscenvivint和JQ1联合治疗可在H3.3K27M突变的弥漫性固有脑桥胶质瘤(DIPG)细胞系中诱导强烈的细胞毒性作用。

Wiese M, et al. Cell Death & Disease 11.8 (2020): 673.

Pyrvinium pamoate


Foscenvivint和Pyrvinium加Bortezomib可降低RPMI-8226BR和KMS-11BR细胞系的细胞活力并增加细胞凋亡率。

Wu C, Oncol Lett. 2022 Jul; 24(1): 205.

Wnt-C59 (C59)


Foscenvivint和Wnt-C59可抑制人胆管癌细胞的生长,并在异种移植模型和硫代乙胺模型中减少肿瘤面积和数量。

Noll AT, et al. World J Hepatol. 2016 Sep 18;8(26):1093-6.

ICG-001相关产品

Epigenetic Reader Domain抑制剂选择性比较

细胞实验数据示例

细胞系 实验类型 给药浓度 孵育时间 活性描述 文献信息
HK-2  Function Assay 10 µM 3 h reduced the expression of TGF-β1, α-SMA, and CTGF after treatment with HHE 23690997
HKC-8  Function Assay 10 µM 24 h abolishes β-catenin–mediated RAS induction 25012166
SH-SY5Y Apoptosis Assay 10 μM 24 h inhibits the neuroprotective effects of hypoxia against PrP (106-126)-mediated neuronal cell death 23900566
L3.6pl Growth Inhibition Assay 1-20 μM 2/4/6 d inhibits the cell growth in a dose-dependent manner 25082960
PANC-1 Growth Inhibition Assay 1-20 μM 2/4/6 d inhibits the cell growth in a dose-dependent manner 25082960
MiaPaCa-2 Growth Inhibition Assay 1-20 μM 2/4/6 d inhibits the cell growth in a dose-dependent manner 25082960
AsPC-1 Growth Inhibition Assay 1-20 μM 2/4/6 d inhibits the cell growth in a dose-dependent manner 25082960
SH-SY5Y Apoptosis Assay 50 μm 24 h blocks the protective effect of melatonin against PrP (106–126)-induced apoptotic signals 25251028
HepT1 Apoptosis Assay 0-100 μM 24 h IC50=34 μM 23266718
HuH6 Apoptosis Assay 0-100 μM 24 h IC50=39 μM 23266718
RLE-6TN  Function Assay 2.5/5/7.5 μM 48 h inhibits TGF-β1-induced α-SMA induction and EMT 22241478
HKC-8 Function Assay 5/10/20 μM 48 h blocks β-catenin-driven gene expression 21816937
LoVo Cytotoxicity assay 10 uM 72 hrs Cytotoxicity against Wnt/beta-catenin signalling dependent human LoVo cells assessed as cell viability at 10 uM after 72 hrs by ATPlite assay ChEMBL
NCI-H1703 Function assay 10 uM 24 hrs Inhibition of TNIK in human NCI-H1703 cells transfected with lentiviral vector 7TFP assessed as reduction of GSK3 inhibitor X activated TNIK-mediated Wnt/TCF/beta-catenin-dependent transcription at 10 uM after 24 hrs by luciferase reporter assay ChEMBL
HCT116 Cytotoxicity assay 10 uM 72 hrs Cytotoxicity against Wnt/beta-catenin signalling dependent human HCT116 cells assessed as cell viability at 10 uM after 72 hrs by ATPlite assay ChEMBL
MCF7 Function Assay 5 μm  inhibits leptin-mediated increased expression of Snail, Slug, and Zeb2 22270359
SW480 Growth Inhibition Assay 2-100 μM IC50=5.8±0.68 μM 15782138
A549 Antiproliferative assay 72 hrs Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, GI50 = 6.1 μM. 24950489
HepG2 Antiproliferative assay 72 hrs Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay, GI50 = 12.7 μM. 24950489
LoVo Antiproliferative assay 72 hrs Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay, GI50 = 15.6 μM. 24950489
HT-29 Antiproliferative assay 72 hrs Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay, GI50 = 17.2 μM. 24950489
HT29 Function assay 24 hrs Inhibition of Wnt signaling in human HT29 cells assessed as inhibition of beta-catenin-mediated Tcf/Lef transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to control, IC50 = 18.7 μM. 24950489
SW480 Function assay Inhibition of CBP binding to beta-casein in human SW480 cells by immunoblot analysis, IC50 = 1.3 μM. 23232060
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
点击查看更多细胞系数据

生物活性

产品描述 ICG-001拮抗Wnt/β-catenin/TCF介导的转录,并特异性结合到启动子结合蛋白(CBP),IC50为3 μM,但不能结合到相关的转录共激活因子p300上。ICG-001 可诱导凋亡。
靶点
CBP [1]
(Cell-free assay)
3 μM
体外研究(In Vitro)
体外研究活性

ICG-001 作用于TOPFLASH 时,IC50为3 μM,而对含突变TCF位点的相关报告基因结构, FOPFLASH没有作用效果。使用25μM ICG-001处理SW480 细胞8小时后,降低Survivin和 Cyclin D1 RNA和蛋白的稳定水平,这两者都可通过β-catenin上调。ICG-001 作用于转化细胞而不是正常结肠细胞,选择性诱导凋亡,降低结肠癌细胞生长。[1] ICG-001作用于presenilin-1突变细胞,可表型营救正常神经生长因子(NGF)诱导的神经元分化和神经轴突生长,强调TCF/β-catenin 信号通路在神经轴突生长和神经元分化中的重要性。[2] 最新研究显示 5μM ICG-001作用于MCF7细胞,抑制leptin诱导的EMT, 入侵和肿瘤干细胞球形成。[3]

实验图片 检测方法 检测指标 实验图片 PMID
Western blot SOX-2 / CD44 / Survivin / EGFR / FOXM1 / EZH2 / Vimentin pβ-catenin beta-catenin / F-actin ABC / Beta-catenin / E-cadherin / N-cadherin / MMP-9 / c-MYC / Actin / Histone H3 CCNB1 / Cyclin D1 25897700
体内研究(In Vivo)
体内研究活性

ICG-001 水溶性类似物处理9周,降低42%结肠和小肠息肉的形成,和非甾体类抗炎试剂Sulindac效果类似,Sulindac是一贯治疗这种疾病模型的药物。在整个的处理期间观察不到明显的毒性。类似物按150 mg/kg 剂量静脉注射处理SW620裸鼠肿瘤衰退移植瘤模型,处理19天,显著降低肿瘤体积,没有死亡,体重也没有降低。[1] ICG-001 每天按5 mg/kg剂量处理小鼠,显著抑制beta-catenin信号,且降低 Bleomycin诱导的肺纤维化,同时保护上皮细胞。[4]

动物实验 Animal Models C57BL/6和裸鼠肿瘤模型
Dosages 20 mg/kg
Administration 腹腔注射

化学信息&溶解度

分子量 548.63 分子式

C33H32N4O4

CAS号 780757-88-2 (relative stereochemistry); 847591-62-2 (absolute stereochemistry) SDF Download ICG-001 SDF
Smiles C1CN(C2CN(C(=O)C(N2C1=O)CC3=CC=C(C=C3)O)CC4=CC=CC5=CC=CC=C54)C(=O)NCC6=CC=CC=C6
储存条件(自收到货起)

体外溶解度
批次:

DMSO : 30 mg/mL ( 54.68 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次:

现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量 浓度 体积 分子量

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
If the compound is stored in DMSO at -80, how long would it be stable? For cell culture, how long should I change for the fresh medium with ICG-001?

回答:
The product in DMSO solution can be stored at 4 degree for 1 week and -20 degree for 1 month. The best storage condition is solid powder, even at -80 the solution is not stable enough for long term storage. For cell culture, you need change medium every 48h.

Tags: buy ICG-001 | ICG-001 supplier | purchase ICG-001 | ICG-001 cost | ICG-001 manufacturer | order ICG-001 | ICG-001 distributor
在线咨询
联系我们